Groups that represent 340B covered entities said they looked forward to studying the federal government’s proposal Tuesday to revamp the 340B administrative dispute process. But they expressed concern that drug manufacturers still are not being punished for denying 340B pricing when entities ship drugs to contract pharmacies to be dispensed.
The brand drug industry said it is still reviewing the proposal and that 340B remains “plagued with abuse.”
Groups that represent 340B covered entities said they looked forward to studying the federal government’s proposal Tuesday to revamp the 340B administrative dispute process, while the brand drug industry said it is still reviewing the proposal and that 340B remains “plagued with abuse.”
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
